About this trial
Postoperative pain control remains suboptimal for a large proportion of surgical patients and is frequently associated with slower recovery and higher reliance on opioids after surgery. Current intraoperative analgesic approaches predominantly use short-acting opioids, whose rapid pharmacokinetics can lead to variable drug exposure and inconsistent control of nociceptive stimuli.
Methadone has a different pharmacologic profile, combining prolonged μ-opioid receptor activity with N-methyl-D-aspartate receptor antagonism, allowing sustained analgesia following a single intraoperative administration and potentially enhancing postoperative recovery.
The MELODY trial is a multicentre, randomized, patient-blinded clinical study designed to compare a single intravenous dose of methadone given at induction with conventional short-acting opioid-based anesthesia in adults undergoing intermediate-risk noncardiac surgery. The primary aim is to evaluate whether this strategy leads to improved quality of recovery on the first postoperative day.
Eligibility criteria
Qualifiers
Age ≥18 years
Elective intermediate-risk noncardiac surgery under general anesthesia
ASA physical status I-III
Expected hospital stay ≥24 hours
Disqualifiers
Severe hepatic dysfunction (Child-Pugh C)
Severe renal impairment (eGFR <30 mL/min/1.73 m²)
Known allergy to methadone or opioids
Pregnancy or breastfeeding
Trial design
Treatments tested in this trial
- Intravenous Methadone
- Short-acting Opioids Intraoperative analgesia
Treatment groups
Sponsors and collaborators
Alexandre P. Joosten
Lead sponsor
University of California, Los Angeles
Sponsor institution